“A Randomized, Single-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD5044 in Healthy Subjects”, this study is ongoing in Australia. the study is currently in the single-dose incremental enrolment phase.

RBD4059 is a GalNAc-siRNA drug that inhibits FXI activity and prolongs APTT to achieve anticoagulant effects. As demonstrated in preclinical data, RBD4059 has a long-lasting and potent antithrombotic effect combined with a favorable safety profile. RBD4059 is the first FXI targeting siRNA drug that that has entered the clinical stage.